Polysomnography

Sleep Apnea Devices Market, Industry Trends and Global Forecasts, 2035

Retrieved on: 
Friday, March 15, 2024
Diagnosis, ResMed, Non-invasive ventilation, Sleep apnea, CPAP, Growth, Prevalence, APAP, LivaNova, Obstructive sleep apnea, Polysomnography, Ageing, Ventilation, Research, Overalls, Central sleep apnea, Woman, Hub, Interest, USD, Administration, Pharmaceutical industry

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points: 
  • The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
  • The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
  • The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
  • Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
    The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

Scientists operated a Cybertruck from dreams (VIDEO)

Retrieved on: 
Monday, February 5, 2024
ResearchGate, Human, Light, Dream, Music, Canadian International Council, PsyArXiv, Polysomnography, Speech, Computer, Inception, Preprint, REM, Eyelid, Movement

REDWOOD CITY, Calif., Feb. 5, 2024 /PRNewswire/ -- Researchers from California startup REMspace have achieved the first two-way control of a virtual object from a lucid dream. The results of the experiment were approved for publication in the scientific journal International Journal of Dream Research.  

Key Points: 
  • The results of the experiment were approved for publication in the scientific journal International Journal of Dream Research.
  • We spend a third of our lives asleep, and humanity dreams of using this time profitably, just as the heroes of the movie Inception did.
  • If a person moved their legs in a dream, this led to the movement of a virtual avatar (Cybertruck) on the computer screen.
  • According to Michael Raduga, leader of the experiment, "Two-way interaction with a computer from dreams opens up a whole area of new technologies.

Onera raises over €30M in Series C funding

Retrieved on: 
Tuesday, January 16, 2024
Digital health, Sleep, PSG, DACH, Health, Partnership, BOM, ONERA, American Academy, Medicine, Generative grammar, Medtech, Polysomnography, AASM, Growth, Pharmaceutical industry

Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round.

Key Points: 
  • Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round.
  • Eindhoven – January 16, 2024 – Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.
  • This latest funding round brings Onera’s total investment to date to more than €55 million.
  • As part of this transaction, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.

Onera raises over €30M in Series C funding

Retrieved on: 
Tuesday, January 16, 2024
Software, General Health, Mobile, Wireless, Hardware, Biometrics, Technology, Medical Devices, Health Technology, Nanotechnology, Neurology, Biotechnology, Wearables, Mobile Technology, Health, Digital health, Sleep, PSG, DACH, Multimedia, Partnership, BOM, ONERA, American Academy, Medicine, Generative grammar, Medtech, Polysomnography, AASM, Growth, Pharmaceutical industry

Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.

Key Points: 
  • Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.
  • This latest funding round brings Onera’s total investment to date to more than €55 million.
  • View the full release here: https://www.businesswire.com/news/home/20240115279169/en/
    Ruben de Francisco, Founder and CEO of Onera Health.
  • As part of this transaction, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.

Tackling the Poor Sleep Pandemic: FRENZ Brainband by Earable Neuroscience Announces Global Sales After CES 2024 Innovation Award Win

Retrieved on: 
Sunday, January 14, 2024
PSG, Sleep, Founders Fund, Polysomnography, University, Foxconn, Fitness, Ageing, Algorithm, Anxiety, MSRP, Investment, Therapy, CES, Neuroscience

BOULDER, Colo., Jan. 14, 2024 /PRNewswire/ -- Following its CES Innovation Award for Aging Technology, Earable® Neuroscience announced the global sales of FRENZ™ Brainband, a groundbreaking AI-powered sleep tech wearable designed to help people sleep better. FRENZ Brainband, paired with the complimentary FRENZ AI Sleep Science app, has been clinically proven to help people fall asleep 24 minutes faster on average, as published on Nature Scientific Report. FRENZ is now ready for shipping globally from frenzband.com. The product is currently trending in the Fitness & Activity Monitors category on Amazon.

Key Points: 
  • BOULDER, Colo., Jan. 14, 2024 /PRNewswire/ -- Following its CES Innovation Award for Aging Technology, Earable® Neuroscience announced the global sales of FRENZ™ Brainband, a groundbreaking AI-powered sleep tech wearable designed to help people sleep better.
  • FRENZ Brainband, paired with the complimentary FRENZ AI Sleep Science app, has been clinically proven to help people fall asleep 24 minutes faster on average, as published on Nature Scientific Report .
  • FRENZ Brainband represents a significant advancement in sleep technology, offering precise tracking and real-time brain activity stimulation using non-invasive audio therapy.
  • "FRENZ is a comprehensive, comfortable, all-in-one sleep wearable that provides real-time, direct stimulation with precise data to effectively address sleep issues.

Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause

Retrieved on: 
Monday, January 8, 2024
Other Health, Research, General Health, Pharmaceutical, Consumer, Mental Health, Clinical Trials, Science, Women, Seniors, Other Science, Health, Psychiatry, WASO, Wakefulness, Metabolism, Woman, VMS, Hot, Executive Committee, Menopause, NIRVANA, Sleep, Field, OASIS, SDM, Safety, Polysomnography, Pharmaceutical industry

The first study participants were recently enrolled into NIRVANA, an exploratory Phase II study to evaluate the efficacy and safety of elinzanetant in women with sleep disturbances associated with menopause (SDM).

Key Points: 
  • The first study participants were recently enrolled into NIRVANA, an exploratory Phase II study to evaluate the efficacy and safety of elinzanetant in women with sleep disturbances associated with menopause (SDM).
  • It is intended to randomize approximately 78 participants in eight countries to investigate the efficacy and safety of elinzanetant in women with sleep disturbances associated with menopause (SDM).
  • The primary endpoint for the NIRVANA study is the efficacy of elinzanetant on Wakefulness After Sleep Onset (WASO) at week 4 as measured by polysomnography.
  • The safety profile observed in the OASIS 1 and 2 studies is overall consistent with previously published data2,6 on elinzanetant.

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Retrieved on: 
Wednesday, December 6, 2023
Obstructive sleep apnea, Deficit spending, Depression, Disease, Ageing, Blood, Claustrophobia, Accident, Dronabinol, Death, Workplace, Metabolic acidosis, Noise, Conditional sentence, Sleep, Amnesia, Patient, Diagnosis, Cardiovascular disease, PAP, Safety, CO2, AHI, PSG, Somnolence, Acetazolamide, Polysomnography, Judgement, Pharmaceutical industry

Obstructive sleep apnea (OSA) is characterised by a narrowing or obstruction of the upper airway during sleep, which interrupts breathing resulting in decreased oxygen uptake and poor sleep quality.

Key Points: 
  • Obstructive sleep apnea (OSA) is characterised by a narrowing or obstruction of the upper airway during sleep, which interrupts breathing resulting in decreased oxygen uptake and poor sleep quality.
  • Incannex has designed IHL-42X, a combination of dronabinol (synthetic THC) and acetazolamide, for treatment of OSA.
  • A video presentation of IHL-42X for the treatment of OSA has been uploaded to the Incannex website, link here: https://www.incannex.com/clinical-trail/ihl-42x-osa/ .
  • This gave Incannex the confidence to proceed with a multisite Phase 2/3 clinical trial further investigating safety and efficacy of IHL-42X in patients with OSA.

DeRUCCI Launches First AIoT Smart Mattress

Retrieved on: 
Wednesday, November 1, 2023
Technology, Men, Retail, Health, Consumer, Home Goods, Artificial Intelligence, Other Technology, Other Retail, IOT (Internet of Things), General Health, Other Consumer, Specialty, Women, Internet of things, FIR, Peter Hancock (professor), Renni Rucci, Human, Temperature, BMI, Heart rate, Aromatherapy, Respiration, LaTeX, PSG, Artificial intelligence of things, Research, Exercise, Multimedia, Artificial intelligence, Sleep, Conditional sentence, Immunity, Thermoregulation, Diet, Polysomnography, Algorithm, T11, Safety, Snoring, AI, Police aviation in the United Kingdom, Tidal, Pharmaceutical industry, Medical device, Carbon fibers, Consumer electronics

The DeRUCCI Group https://www.derucci.com , a leading public company and sleep technology brand, launched today the DeRUCCI T11 Pro Smart Mattress, an Artificial Intelligence of Things (AIoT) intelligent sleep solution.

Key Points: 
  • The DeRUCCI Group https://www.derucci.com , a leading public company and sleep technology brand, launched today the DeRUCCI T11 Pro Smart Mattress, an Artificial Intelligence of Things (AIoT) intelligent sleep solution.
  • Based on extensive sleep/health research conducted by DeRUCCI with international universities and institutions, the DeRUCCI T11 Pro Smart Mattress is the first smart mattress that instantly adjusts to the individual’s health for optimal sleep; actually warning the user about potential health issues before they are aware of them.
  • The DeRUCCI smart mattress employs big data based on 1.08 billion pieces of sleep data, AI software algorithms, smart software/hardware adjustments, and sleep monitoring; and connects to other AIoT home appliances to control the bedroom’s smart thermostat, air conditioner, aromatherapy, air purifier, sleep-enhancing lighting, meditation products, sleep aids, and other IoT devices.
  • The DeRUCCI T11 Pro AIoT Smart Mattress is available immediately in China and in the U.S. in Q3 2024, priced at $8,250.

Study Reveals Exciting Benefits of Using a Low Dose Valerian Extract for Sleep Quality and Occasional Anxiety

Retrieved on: 
Wednesday, November 1, 2023
Female, FACN, Pittsburgh Sleep Quality Index, Narcolepsy, Doctor of Philosophy, Research, Sleep, Male, Safety, Anxiety, Regulatory affairs, Pharmaceutical industry, Consumer electronics, Nursing, Polysomnography

The study revealed that Sleeproot significantly improved sleep quality scores based on the Pittsburgh Sleep Quality Index questionnaire, as well as:

Key Points: 
  • The study revealed that Sleeproot significantly improved sleep quality scores based on the Pittsburgh Sleep Quality Index questionnaire, as well as:
    reduced sleep latency, allowing participants to fall asleep more quickly.
  • "This study shows that Sleeproot, a low dose valerian extract, at a 2% valerenic acid potency, can significantly improve aspects of sleep quality, as measured by validated quantitative and qualitative sleep methodologies."
  • The research included regular study visits to monitor outcomes related to sleep quality and occasional anxiety.
  • Using a combination of validated sleep assessment tools, including the Pittsburgh Sleep Quality Index, Wrist Actigraphy, and Polysomnography, researchers measured various parameters of sleep quality.

HoneyNaps Receives U.S. FDA Approval for Groundbreaking AI Sleep Disorder Diagnosis Software

Retrieved on: 
Monday, September 25, 2023
Posture, Polysomnography, Sleep, AlphaGo, WSS, Research, Snoring, XAI, Facial muscles, Sleep disorder, SCIE, Reading, Diagnosis, AI, Chin, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical device, Pharmaceutical industry

SEOUL, South Korea, Sept. 25, 2023 /PRNewswire/ -- HoneyNaps, the leading-edge AI-based sleep disorder diagnosis software company, has announced that its SOMNUM AI sleep disease analysis algorithm has been approved by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • SEOUL, South Korea, Sept. 25, 2023 /PRNewswire/ -- HoneyNaps, the leading-edge AI-based sleep disorder diagnosis software company, has announced that its SOMNUM AI sleep disease analysis algorithm has been approved by the U.S. Food and Drug Administration (FDA).
  • AI and medical devices are a sought-after combination, but the FDA has granted only two approvals for sleep disease diagnosis solutions by U.S. companies.
  • HoneyNaps is the first Korean company and identify their FDA approval as a demonstration of their technology's capabilities.
  • Sleep biosignals tend to include electroencephalograms, electrooculograms, chin and leg electromyograms, electrocardiograms, respiratory airflow and effort, oxygen saturation, posture, and snoring, and these are monitored continuously during sleep for assessing sleep status and sleep disorder diagnosis via polysomnography.